4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

Craig Hallum initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $109.00

Mizuho initiated coverage of Apogee Therapeutics with a rating of Outperform and set a new price target of $105.00

RBC Capital Mkts initiated coverage of Apogee Therapeutics with a rating of Outperform and set a new price target of $60.00

BTIG Research reiterated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $115.00 from $100.00 previously

Citigroup initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $95.00

Canaccord Genuity initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $89.00

BofA Securities initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $80.00

BTIG Research initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $43.00

TD Cowen initiated coverage of Apogee Therapeutics with a rating of Outperform

Wedbush initiated coverage of Apogee Therapeutics with a rating of Outperform and set a new price target of $40.00

144 - Apogee Therapeutics, Inc. (0001974640) (Subject)

10-Q - Apogee Therapeutics, Inc. (0001974640) (Filer)

8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)

SCHEDULE 13D/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)

424B5 - Apogee Therapeutics, Inc. (0001974640) (Filer)

424B5 - Apogee Therapeutics, Inc. (0001974640) (Filer)

10-Q - Apogee Therapeutics, Inc. (0001974640) (Filer)

8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)

SCHEDULE 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B data in AD in Q2 2026, and APG279 Phase 1b head-to-head readout against DUPIXENT in AD in 2H 2026 Interim Phase 1 results of APG333 in healthy volunteers reported today exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6-month dosing and the development of a quarterly or less frequently dosed co-formulation of APG273 (APG777+APG333)

Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month dosing Results support development of a quarterly or less frequently dosed co-formulation of APG273 (APG777+APG333) for respiratory indications APG333 was well tolerated across all cohorts with doses of up to 1,000 mg SAN FRANCISCO and BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunol

SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will participate at the following investor conferences. Guggenheim 2nd Annual Healthcare Innovation Conference Date: Tuesday, November 11, 2025Fireside Chat Time: 1:30 p.m. ET Stifel 2025 Healthcare ConferenceDate: Wednesday, November 12, 2025Fireside Chat Time: 11:20 a.m. ET TD Cowen Immunology and Inflammation Virtual Summit  Date: Thursday, November 13, 2025Fireside Chat Time: 12:30 p.m. ET Jefferies London Healthcare Conference Date: Wednesday, November 19, 2025Fireside Chat Time: 3:00 p.m. GMT / 10:00 a.m. ET Citi 2025 Global Healthcare

SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the closing of its previously announced underwritten public offering of 8,048,782 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 1,097,561 additional shares, at a public offering price per share of $41.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 365,853 shares of its common stock at a public offering

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the pricing of its previously announced underwritten public offering of 6,951,221 shares of its common stock at a public offering price per share of $41.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 365,853 shares of its common stock at a public offering price of $40.99999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.00001 pe

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock at the public offering price, less underwriting discount

SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced data from the Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis was accepted for a late-breaker oral presentation at the upcoming EADV Congress 2025, to be held in Paris, France from September 17-20, 2025. The Company will also present multiple poster presentations highlighting APG777's best-in-class potential including data supporting its combination strategy. "These presentatio

SAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025, at 11:30 a.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About ApogeeApogee Therapeutics is a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest I&I markets, including for the treatment of Atopic Dermatitis (AD), asthma, Eos

Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX Part A testing every 3- or 6-month maintenance dosing, a significant improvement versus standard of care which is dosed every two weeks, is ongoing with 52-week readout anticipated in 1H 2026 Driven by strong enrollment, APEX Phase 2 Part B of APG777 readout accelerated to mid-2026 First patient dosed in Phase 1b head-to-head trial of APG279 (IL-13 + OX40L) vs. DUPIXENT in atopic dermatitis, with readout expected in 2H 2026 $621.2 million cash, cash equivalents and marketable securities suppor

APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% placebo-adjusted) at Week 16, the highest topline and placebo-adjusted efficacy of any biologic in a global study Exposure-response relationship observed across multiple key endpoints; APEX Part B is testing higher exposures with readout accelerated and now anticipated mid-2026, enabling planned Phase 3 initiation in 2026 APEX Part A testing potentially best in class 3- or 6-month maintenance dosing with 52-week readout anticipated 1H 2026 APG777 was well tolerated with a favorable safety profi

SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET. Featured Speakers:Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new t

SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of

SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy,

SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Lisa Bollinger, MD, has been appointed to the company's board of directors. Dr. Bollinger most recently served as Vice President, Regulatory Affairs, Global Regulatory Affairs and Clinical Safety (GRACS) at Merck, where she led the general medicine therapeutic area in regulatory affairs. Dr. Bollinger's over 30 years of experience in drug development,

SAN FRANCISCO and WALTHAM, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease and other inflammatory and immunology (I&I) indications, today announced the appointment of Mark C. McKenna as Chairman of its board of directors. Mr. McKenna's knowledge and successful track record in the I&I space as well as his significant development, commercial and executive management experience contributed to the Apogee board of directors' selection decision. "We are thrilled to welcome Mark as chair of our board and to

SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)

SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)

SC 13D/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% placebo-adjusted) at Week 16, the highest topline and placebo-adjusted efficacy of any biologic in a global study Exposure-response relationship observed across multiple key endpoints; APEX Part B is testing higher exposures with readout accelerated and now anticipated mid-2026, enabling planned Phase 3 initiation in 2026 APEX Part A testing potentially best in class 3- or 6-month maintenance dosing with 52-week readout anticipated 1H 2026 APG777 was well tolerated with a favorable safety profi

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report Part A 16-week data from the Phase 2 APEX trial of APG777 on Monday, July 7, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Detai

SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report interim results from the Phase 1 APG990 healthy volunteer trial on Monday, March 3, 2025. Following the announcement, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for i

Pharmacokinetic data support potential best-in-class profile with potential for improved clinical responses from greater exposures in induction than currently available biologic therapies and maintenance dosing of every 3- or 6-months Single dose showed deep and sustained inhibition of key atopic dermatitis biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available with inhibition still ongoing at time of data cut) APG777 was well tolerated with a favorable safety profile consistent with the anti-IL-13 class Company plans to initiate a randomized, placebo-controlled, 16-week Phase 2 clinical trial in patients with moderate-to-severe atopic dermatitis in 1H 2024 with induction r

SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I) indications, today announced it will report interim results from the Phase 1 APG777 healthy volunteer trial on Tuesday, March 5, 2024. Following the announcement, the Company will host a conference call and webcast at 7:00am ET to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Apogee's website at https://investors.apogeeth